Stay updated with breaking news from Brian Lian. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Viking Therapeutics reports quarterly losses of 26 cents per share which beat the analyst consensus estimate of losses of 28 cents by 7.14%. Research and development expenses were $24.1 million for the first quarter, compared to $11 million for the same period in 2023.
/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...
:max_bytes(150000):strip_icc()/GettyImages-95468959-56aa07283df78cf772ac130e.jpg)
Viking Therapeutics shares jumped after the company reported its experimental oral weight-loss drug showed positive results in an early trial.
Viking Therapeutics' VK2735, a dual GLP-1 and GIP receptor agonist, achieved significant weight loss (up to 14.7%) in metabolic disorder patients. Safe, well-tolerated treatment with no observed plateau.
Viking Therapeutics Inc (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, has reported a significant insider sell according to the latest SEC filings.